Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Update on Non- Cystic Fibrosis Bronchiectasis.

QJM : monthly journal of the Association of Physicians·2026

Same author

The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL).

Leukemia & lymphoma·2026

Same author

Paradigm shifts in asthma: what is old is new again.

The Lancet. Respiratory medicine·2025

Same author

Genetic and phenotypic diversity of wine-associated Hanseniaspora species.

FEMS yeast research·2025

Same author

Illustrated capsules from the Advanced Course in Platelet Research.

Research and practice in thrombosis and haemostasis·2025

Same author

A robust evaluation of TDP-43, poly GP, cellular pathology and behavior in an AAV-C9ORF72 (G<sub>4</sub>C<sub>2</sub>)<sub>66</sub> mouse model.

Acta neuropathologica communications·2024

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.

Andrew C Nyborg¹, Chris Ward¹, Anna Zacco¹

¹MedImmune LLC, Gaithersburg, Maryland, United States of America.

|December 22, 2016

Summary

A novel, non-immunogenic uricase enzyme was engineered to treat gout by lowering uric acid levels. This therapeutic uricase demonstrates high efficacy and reduced immunogenicity, offering a promising new treatment for chronic refractory gout.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: Mar 9, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

Biochemistry
Immunology
Drug Development

Background:

Humans lack uricase, leading to high serum uric acid and gout.
Current uricase therapies can cause severe immunogenic responses, limiting their use.
Chronic refractory gout requires innovative treatment options.

Purpose of the Study:

To engineer a novel, non-immunogenic uricase with improved therapeutic properties.
To assess the efficacy and safety of the engineered uricase in preclinical models.
To develop a potential new treatment for chronic refractory gout.

Main Methods:

Protein engineering guided by sequence alignment of over 200 uricase sequences.
Identification of a lead uricase candidate with low immunogenicity potential.
Site-specific PEGylation of the lead candidate and in vitro/in vivo efficacy studies.

Main Results:

Engineered uricase exhibits improved solubility, stability, and activity.
Demonstrated >95% PEGylation efficiency with retained enzymatic function.
Achieved an 85% reduction in serum uric acid in canines after a single dose.

Conclusions:

The developed PEGylated, non-immunogenic uricase shows significant potential for treating gout.
This novel enzyme offers a safer and more effective alternative to existing therapies.
Further clinical studies are warranted to validate its therapeutic benefits in patients.